Merck Likely to Post Inline Q2 Revenue, RBC Says
Merck's (MRK) Q2 revenue is likely to be in line with consensus estimates as its Keytruda immunotherapy and Gardasil HPV vaccine sales are tracking at expected levels, RBC Capital Markets said in a Wednesday research report. The brokerage said its revenue estimate for fiscal 2026 is higher than the company's guidance, implying room for a potential upward revision. The company is due to report Q2 results on Aug. 4. Keytruda's US growth continues at a more moderate pace, as it nears peak penetration in key tumor types amid looming global pricing headwinds, while Gardasil growth should be stable from a year earlier excluding China, according to the note. The brokerage said it reiterated its outperform rating on the stock and price target of $142 per share. Price: $126.18, Change: $-2.68, Percent Change: -2.08%
Merck's (MRK) Q2 revenue is likely to be in line with consensus estimates as its Keytruda immunotherapy and Gardasil HPV vaccine sales are tracking at expected levels, RBC Capital Markets said in a Wednesday research report.
The brokerage said its revenue estimate for fiscal 2026 is higher than the company's guidance, implying room for a potential upward revision.
The company is due to report Q2 results on Aug.
4.
Keytruda's US growth continues at a more moderate pace, as it nears peak penetration in key tumor types amid looming global pricing headwinds, while Gardasil growth should be stable from a year earlier excluding China, according to the note.
The brokerage said it reiterated its outperform rating on the stock and price target of $142 per share.
Price: $126.18, Change: $-2.68, Percent Change: -2.08%